BIOX on Nasdaq
Bioceres Crop Solutions Corp.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with AMERICAN VANGUARD CORP, CVR PARTNERS, LP or The Scotts Miracle-Gro Company, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
39.3%Gross margin2
-0.7%Operating margin2
-17.6%Net margin2
-27.9%Revenue growth, 20252
-19.9%Return on equity2
$44.3MFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Crop protection brought in 54% of the revenue Bioceres Crop Solutions Corp. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Crop protection | $205.8M | $223.5M | $181.9M |
| Crop nutrition | $157.3M | $144.8M | $89.5M |
| Seed and integrated products | $56.9M | $96.4M | $63.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs100¢$335.1M
Out of $335.1M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending11¢$5.6M
- Kept or used elsewhere89¢$44.3M
Out of $49.9M of cash from operations.2
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|
| Revenues from contracts with customers | $333.3M | $464.8M | $419.4M |
| Initial recognition and changes in the fair value of biological assets at the point of harvest | $1.8M | -$45.7K | $610.6K |
| Cost of sales | -$203.4M | -$278.2M | -$235.5M |
| Changes in the net realizable value of agricultural products after harvest | -$1.5M | -$2.4M | -$4.4M |
| Research and development expenses | -$14.9M | -$17.2M | -$15.3M |
| Selling, general and administrative expenses | -$123.1M | -$123.7M | -$113.0M |
| Share of profit or loss of joint ventures and associates | -$1.1M | $4.0M | $1.2M |
| Other income or expenses, net | $6.8M | -$1.5M | $1.1M |
| Operating (loss)/ profit | -$2.2M | $45.9M | $54.2M |
| Financial cost | -$28.8M | -$26.9M | -$23.8M |
| Other financial results | -$26.5M | -$7.9M | -$11.3M |
| (Loss)/ Profit before income tax | -$57.6M | $11.1M | $19.1M |
| Income tax | -$1.3M | -$3.8M | $1.1M |
| (Loss)/ Profit for the year | -$58.8M | $7.3M | $20.2M |
| Equity holders of the parent | -$55.4M | $4.3M | $18.8M |
| Non-controlling interests | -$3.4M | $3.0M | $1.4M |
| Basic loss attributable to ordinary equity holders of the parent | -$0.88 | $0.07 | $0.30 |
| Diluted loss attributable to ordinary equity holders of the parent | -$0.88 | $0.07 | $0.30 |
| Other comprehensive (loss) | -$714.3K | -$787.4K | -$835.8K |
| Items that may be subsequently reclassified to (loss)/ profit | -$714.3K | -$787.4K | $631.5K |
| Foreign exchange differences on translation of foreign operations from joint ventures | -$238 | -$46.9K | |
| Foreign exchange differences on translation of foreign operations | -$714.3K | -$787.1K | $678.4K |
| Items that will not be subsequently reclassified to loss and profit | -$1.5M | ||
| Revaluation of property, plant and equipment, net of tax, of joint ventures and associates 1 | -$184.6K | ||
| Revaluation of property, plant and equipment, net of tax 2 | -$1.3M | ||
| Equity holders of the parent | -$56.0M | $3.8M | $17.9M |
| Non-controlling interests | -$3.6M | $2.7M | $1.4M |
| Total comprehensive (loss)/ profit | -$59.6M | $6.5M | $19.3M |
| Tax effect of the revaluation of property, plant and equipment of joint venture and associates | $99.4K | ||
| Tax effect of the revaluation of property, plant and equipment | $703.1K |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $32.7M | $44.5M | |
| Other financial assets | $2.0M | $11.7M | |
| Trade receivables | $165.9M | $207.3M | |
| Other receivables | $15.9M | $18.3M | |
| Recoverable income tax | $1.9M | $655.7K | |
| Inventories | $87.6M | $125.9M | |
| Biological assets | $2.4M | $294.1K | $146.8K |
| Total current assets | $308.3M | $408.7M | |
| Other financial assets | $58 | $634.6K | |
| Trade receivables | $2.5M | ||
| Other receivables | $23.7M | $18.0M | |
| Recoverable income tax | $18.0K | $10.9K | |
| Deferred tax assets | $4.9M | $9.7M | |
| Investments in joint ventures and associates | $39.4M | $39.8M | |
| Investment properties | $570.3K | $560.8K | |
| Property, plant and equipment | $74.6M | $74.6M | $67.9M |
| Intangible assets | $181.2M | $176.9M | $173.8M |
| Goodwill | $112.2M | $112.2M | |
| Right of use asset | $16.4M | $11.6M | |
| Total non-current assets | $455.3M | $443.9M | |
| Total assets | $763.6M | $852.5M | |
| Trade and other payables | $96.4M | $168.7M | |
| Borrowings | $119.7M | $136.7M | |
| Employee benefits and social security | $6.2M | $7.3M | |
| Deferred revenue and advances from customers | $4.3M | $3.9M | |
| Income tax payable | $452.8K | $4.8M | |
| Consideration for acquisition | $1.8M | $4.6M | |
| Secured notes | $102.3M | ||
| Lease liabilities | $6.9M | $3.1M | |
| Total current liabilities | $338.0M | $329.3M | |
| Trade and other payables | $48.5M | ||
| Borrowings | $38.2M | $42.1M | |
| Deferred revenue and advances from customers | $1.4M | $1.9M | |
| Joint ventures and associates | $1.0M | $296.5K | |
| Deferred tax liabilities | $30.1M | $35.0M | |
| Provisions | $1.3M | $1.3M | |
| Consideration for acquisition | $397.8K | $2.3M | |
| Secured notes | $80.8M | ||
| Lease liabilities | $9.5M | $8.2M | |
| Total non-current liabilities | $130.4M | $171.9M | |
| Total liabilities | $468.4M | $501.2M | |
| Equity attributable to owners of the parent | $265.4M | $315.0M | |
| Non-controlling interest | $29.8M | $36.3M | |
| Total equity | $295.2M | $351.4M | $330.5M |
| Total equity and liabilities | $763.6M | $852.5M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|
| (Loss)/ Profit for the year | -$58.8M | $7.3M | $20.2M |
| Income tax | $1.3M | $3.8M | -$1.1M |
| Financial results | $55.3M | $34.8M | $35.1M |
| Depreciation of property, plant and equipment | $6.0M | $5.8M | $4.8M |
| Amortization of intangible assets | $11.2M | $12.1M | $11.0M |
| Depreciation of leased assets | $5.0M | $3.4M | $3.6M |
| Transactional expenses | $4.0M | $1.1M | $4.2M |
| Share-based incentive and stock options | $4.4M | $14.1M | $3.4M |
| Share of profit or loss of joint ventures and associates | $1.1M | -$4.0M | -$1.2M |
| Loss of participation in joint ventures and associates | $133.1K | ||
| Gain from a bargain purchase | -$1.0M | ||
| Provisions for contingencies | $335.8K | $367.1K | $221.0K |
| Allowance for impairment of trade debtors | $7.1M | $753.4K | $1.3M |
| Allowance for obsolescence | $1.5M | $586.5K | $1.1M |
| Initial recognition and changes in the fair value of biological assets | -$1.8M | $45.7K | -$610.6K |
| Changes in the net realizable value of agricultural products after harvest | $1.5M | $2.4M | $4.4M |
| Gain on sale of equipment and intangible assets | -$7.8M | -$125.5K | -$74.6K |
| Trade receivables | $25.5M | -$46.7M | -$56.9M |
| Other receivables | -$916.4K | -$5.0M | -$11.5M |
| Income and minimum presumed income taxes | -$7.0M | $4.8M | -$16.2M |
| Inventories and biological assets | $34.9M | $14.2M | -$11.1M |
| Trade and other payables | -$32.0M | $14.2M | -$4.5M |
| Employee benefits and social security | -$1.2M | -$2.3M | $1.3M |
| Deferred revenue and advances from customers | -$128.7K | -$21.1M | $13.3M |
| Income taxes paid | -$853.3K | -$4.1M | |
| Interest collected | $120.6K | $2.7M | $5.4M |
| Inflation effects on working capital adjustments | $139.9K | $321.1K | $376.6K |
| Net cash flows generated by operating activities | $49.9M | $41.7M | $2.6M |
| Proceeds from sale of property, plant and equipment | $390.4K | $336.7K | $137.4K |
| Net cash received from business combination | $37.5K | $4.4M | |
| Proceeds from financial assets | $19.3M | $888.1K | $1.3M |
| Investment in financial assets | -$11.2M | -$7.2M | -$9.0M |
| Purchase of property, plant and equipment | -$5.6M | -$9.8M | -$11.4M |
| Capitalized development expenditures | -$8.6M | -$11.9M | -$10.8M |
| Purchase of intangible assets | -$350.8K | -$1.1M | -$449.7K |
| Net cash flows used by investing activities | -$6.1M | -$28.7M | -$25.7M |
| Proceeds from borrowings | $266.4M | $135.8M | $79.8M |
| Repayment of borrowings and financed payments | -$288.5M | -$112.6M | -$16.7M |
| Interest payments | -$18.9M | -$24.7M | -$18.0M |
| Other financial payments | -$3.2M | -$2.7M | -$4.8M |
| Purchase of own shares | -$926.9K | -$734.4K | -$3.0M |
| Leased assets payments | -$5.5M | -$4.9M | -$3.9M |
| Cash dividend distributed by subsidiary | -$72.1K | -$174.8K | -$452.1K |
| Net cash flows (used by)/ generated by financing activities | -$50.7M | -$10.1M | $33.0M |
| Net (decrease)/ increase in cash and cash equivalents | -$6.9M | $2.9M | $9.8M |
| Inflation effects on cash and cash equivalents | $2.6K | -$31.9K | -$101.8K |
| Effect of exchange rate changes on cash and equivalents | -$4.9M | -$6.6M | $4.9M |
Recent filings
- Sep 21, 20266-K
- Sep 16, 20266-K
- Aug 10, 20264/A OWNERSHIP DOCUMENT
- Aug 6, 20264 OWNERSHIP DOCUMENT
- Aug 4, 20264 OWNERSHIP DOCUMENT
- Jul 7, 2026SCHEDULE 13D/A
- Jun 22, 20266-K
- Jun 1, 20266-K
- Jun 1, 2026SCHEDULE 13D/A
- May 12, 20266-K
- May 12, 20263 OWNERSHIP DOCUMENT
- May 11, 20263 OWNERSHIP DOCUMENT
- May 11, 20263 OWNERSHIP DOCUMENT
- May 11, 20263/A OWNERSHIP DOCUMENT
- Apr 28, 2026SCHEDULE 13D/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8